ReviewJournal of clinical medicine2021
Management of Lupus Nephritis.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05207358 (Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis During the Induction of Remission Period-EUROLUPUS vs. RITUXILUP Regimen), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis During the Induction of Remission Period-EUROLUPUS vs. RITUXILUP Regimen: A Randomized Study
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of adding voclosporin to standard treatment of lupus nephritis in adult patients: a meta-analysis and time-to-event analysis of randomized controlled trials.International urology and nephrology · 2026Pooled it
- Successful Cyclosporine Salvage Therapy in Refractory Lupus Nephritis: A Case Study From Ethiopia.Current therapeutic research, clinical and experimental · 2026Article
- Reduction in Renal Relapse and Preservation of Long-Term Kidney Function After Lupus Low Disease Activity in Patients With Lupus Nephritis.Arthritis care & research · 2026Article
- Alpha-1-antichymotrypsin: a potential inducer for epithelial-mesenchymal transition in lupus nephritis.Open life sciences · 2026Article
- Immunological Avalanches in Renal Immune Diseases.Biomedicines · 2025Review
- HDAC6 promotes inflammation in lupus nephritis mice by regulating transcription factors MAFF and KLF5 in renal fibrosis.Renal failure · 2024Article
- Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.Cureus · 2024Review
- Deep learning model to predict lupus nephritis renal flare based on dynamic multivariable time-series data.BMJ open · 2024Article
- Optimal treatment targets for lupus nephritis using per-protocol repeat kidney biopsy findings at 2 years and clinical data up to 5 years: a single-center observational study.Therapeutic advances in chronic disease · 2024Article
- The pharmacological mechanism ofHeliyon · 2023Review
- Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?Kidney international reports · 2023Review
- Four trajectories of 24-hour urine protein levels in real-world lupus nephritis cohorts.RMD open · 2023Article
- Renal C4d is a potential biomarker of disease activity and severity in pediatric lupus nephritis patients.Frontiers in pediatrics · 2023Article
- Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.Human vaccines & immunotherapeutics · 2022Review
- Anxiety and depression prevalence and their risk factors in lupus nephritis patients: A case-control study.Immunity, inflammation and disease · 2022Article
- Efficacy and Safety of Rituximab Therapy for Lupus Nephritis Among SLE Female Patients; a Retrospective Hospital-Based Study.Open access rheumatology : research and reviews · 2022Article
- Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants.Journal of clinical medicine · 2021Review
- Harnessing T-cell therapy for lupus nephritis: Opportunities and challenges.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. To improve the prognosis of LN, recent data suggest that we should
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.